COMMUNICATION
News & Press Release
Total 122
-
112Neurobiogen's Technology for Obesity Treatment is Fastening...
DATE : 2024-12-13
VIEW : 2195
-
111Neurobiogen enters into Licensing Agreement with U.S. pharmaceutical companies for dementia and obes
DATE : 2024-12-12
VIEW : 2208
-
110Scilex Bio Enters into Licensing Agreement with Neurobiogen
DATE : 2024-12-12
VIEW : 2345
-
109CNR Research Performs Neurobiogen's Alzheimer's and Obesity Treatments Clinical Trials Phase2a
DATE : 2024-09-20
VIEW : 2256
-
108CNR Research and Neurobiogen, Alzheimer's and Obesity Treatments Approved by the Ministry of Food an
DATE : 2024-09-19
VIEW : 2289
-
107CNR Research and Neurobiogen Collaborate on Clinical Trial of Alzheimer's New Drug Candidate 'Tisola
DATE : 2024-09-19
VIEW : 2333
-
106CNR Research, Neurobiogen Collaborate on Clinical Trials of New Drug Candidates for Alzheimer's and
DATE : 2024-09-19
VIEW : 2318
-
105100 Billion Won Investment Obesity Drug Enters Phase 2... Neurobiogen's Perseverance.
DATE : 2024-09-09
VIEW : 2275
-
104Neurobiogen. Obesity Treatment Phase 2 Clinical Trial Receives IND Approval from Ministry of Food an
DATE : 2024-09-04
VIEW : 2353
-
103Neurobiogen, Obesity Treatment Approved for Phase 2 Clinical Trial… “Speeding Up Innovative New Drug
DATE : 2024-09-04
VIEW : 2320
- Add(06714) 2 FL, Bangbae BLDG, 9, Myeongdal-ro, Seocho-gu, Seoul, Republic of Korea
- Tel+82-70-4018-8009
- Fax+82-02-3486-2613
- E-mailneuro_reply@neurobiogen.com
FAMILY SITE
COPYRIGHT ⓒ 2025 NEUROBIOGEN. All rights reserved